
The FDA has announced that it has chosen to approve Vosevi (sofosbuvir/velpatasvir/voxilaprevir), Gilead’s investigational drug for the treatment of chronic …
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership

